Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women’s health care.



Research of other conditions is already underway. Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions.



Juneau Biosciences’ knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women. We plan to form strategic alliances with health care partners that will complement our technologies and capabilities in order to commercialize these novel discoveries.